RecruitingPhase 4NCT07148739

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Arkansas Children's Hospital Research Institute
Principal Investigator
Jennifer S Guimbellot, Medical Degree and License
Arkansas Children's Hospital Research Institute
Intervention
Elexacaftor / Ivacaftor / Tezacaftor(drug)
Enrollment
95 target
Eligibility
3 years · All sexes
Timeline
20252030

Study locations (2)

Collaborators

National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07148739 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials